Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Eli Lilly and Company discovers ... It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children. Reuters, the news and media division of Thomson Reuters, ...

That growth includes a one-time benefit of $300 million due to an amendment to Eli Lilly's collaboration with its Jardiance partner Boehringer Ingelheim. The results also kick off a critical year ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a connected ecosystem.

Administration at the hatchery secures early protection for chicks. With VAXXITEK ® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK ® range with a new vaccine that protects ...